Cargando…
Model-based optimization of controlled release formulation of levodopa for Parkinson’s disease
Levodopa is currently the standard of care treatment for Parkinson’s disease, but chronic therapy has been linked to motor complications. Designing a controlled release formulation (CRF) that maintains sustained and constant blood concentrations may reduce these complications. Still, it is challengi...
Autores principales: | Arav, Yehuda, Zohar, Assaf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517026/ https://www.ncbi.nlm.nih.gov/pubmed/37739971 http://dx.doi.org/10.1038/s41598-023-42878-5 |
Ejemplares similares
-
Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013) -
Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023) -
Model-based dietary optimization for late-stage, levodopa-treated, Parkinson’s disease patients
por: Guebila, Marouen Ben, et al.
Publicado: (2016) -
Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy
por: Espay, Alberto J., et al.
Publicado: (2017) -
Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
por: Margolesky, Jason, et al.
Publicado: (2017)